News & Articles
Selected Filters:
QIAGEN adds dPCR platform QIAcuity to growing portfolio of COVID-19 testing solutions
Digital PCR for COVID-19 wastewater testing overcomes limitations of traditional PCR
QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus
QIAstat-Dx and NeuMoDx tests continue to detect all known viral variants extremely effectively
QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets
Test adds to QIAGEN’s growing portfolio of PCR testing solutions for COVID-19 testing
QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour
QIAreach SARS-CoV-2 Antigen Test is an important step towards decentralized mass screening by processing samples in 2–15 minutes
QIAGEN acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems
Menu of test solutions for infectious diseases – which already includes COVID-19 – to be expanded, especially in the U.S.
QIAGEN to launch rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, aims to provide accurate results in less than 15 minutes
QIAGEN expands integrated coronavirus NGS and software solutions
QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research
QIAGEN to launch easy-to-use test in the U.S. for rapid detection of SARS-CoV-2 antibodies
Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies
QIAGEN gains funding for approval process of QIAstat-Dx test kit for COVID-19
The test kit aims to differentiate novel coronavirus from 21 other pathogens implicated in respiratory syndromes
FFPE and Liquid Biopsy PIK3CA diagnostics to enhance precision medicine in advanced breast cancer
QIAGEN launches therascreen PIK3CA RGQ PCR Kit in Europe
QIAGEN to Deliver Genomic Insights For Japan’s New Molecular Oncology Clinical Research and Precision Medicine Initiative
Japan selects QIAGEN Clinical Insight-Interpret to handle next-generation sequencing data
QIAGEN and McKesson Agree to Distribute QIAstat-Dx to Smaller Hospitals in the United States
Agreement adds commercial firepower for QIAGEN’s U.S. launch of the next-generation platform for syndromic insights initially for respiratory conditions
Curetis’ Subsidiary Ares Genetics and QIAGEN Enter into Bioinformatics Partnership to Fight Antimicrobial Resistance
QIAGEN becomes exclusive partner for bioinformatics research applications based on ARESdb and AREStools
QIAGEN and Natera to Develop Cutting-Edge Pre-Natal Genetic Testing Assays
Non-invasive, cell-free pre-natal DNA testing to be performed on QIAGEN’s GeneReader NGS System
Dentognostics Enters into Dental Partnership with QIAGEN to Improve Detection of Inflammation Processes that Damage Dental Implants
aLF Reader and ImplantSafeDR test accurately detect damaging inflammation earlier than traditional methods to better protect dental implants
QIAGEN and Clinical Genomics Partner on Liquid Biopsies to Monitor Patients for Recurrence of Colorectal Cancer
Convenient blood test uses novel technology to test for recurrence of tumors by detecting circulating DNA
New Research Suggests Potential for Additional Clinical Utility of QIAGEN’s Quantiferon-TB Gold Plus
Findings indicate increased specificity in low-risk populations and potential for monitoring tuberculosis treatment
QIAGEN GeneReader NGS System Gains Further Validation in Oncology Research Applications with New Independent Performance Review Data
QIAGEN’s GeneReader NGS System Gains Further Validation in Oncology Research Applications with New Independent Performance Review Data